Analyze Diet
Irish veterinary journal2007; 60(12); 728-731; doi: 10.1186/2046-0481-60-12-728

Resistance studies of erythromycin and rifampin for Rhodococcus equi over a 10-year period.

Abstract: This study sought to determine whether an increase in resistance of Rhodococcus equi to the antibiotics rifampin and erythromycin occurred over a 10-year period. This was carried out by the use of E test strips for rifampin and erythromycin to determine the MIC (minimum inhibitory concentration) values of Rhodococcus equi to this combination of antibiotics.The findings of this study indicated that there was an increase in resistance of Rhodococcus equi to rifampin and erythromycin over the 10-year period. The MIC for rifampin increased from 0.081 μg/ml in 1996 to 0.187 μg/ml in 2006 and from 0.258 μg/ml for erythromycin during the years prior to 2000 to 0.583 μg/ml in 2006.This finding suggests that there may be a problem in the treatment of Rhodococcus equi infections in foals in the future, particularly as the number of drugs available for treatment of Rhodococcus equi infection is limited because of the intracellular capabilities of this bacterium. Antibiotics used in its treatment have to be able to penetrate the polysaccharide cell wall of Rhodococcus equi as well as the alveolar macrophages in which the bacterium is capable of surviving.
Publication Date: 2007-12-01 PubMed ID: 21851690PubMed Central: PMC3113830DOI: 10.1186/2046-0481-60-12-728Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article examines how the resistance of the bacterium Rhodococcus equi to the antibiotics erythromycin and rifampin has increased over a decade. The conclusion drawn is that the increasing resistance could pose challenges to treating infections caused by Rhodococcus equi in the future.

Research Methodology

  • Using E test strips, the study tested for Rhodococcus equi’s minimum inhibitory concentrations (MICs) to rifampin and erythromycin (antibiotics used to treat conditions caused by this bacterium).
  • The MIC value indicates the lowest concentration of an antimicrobial agent that inhibits visible growth of a microorganism.
  • By assessing MIC values from the 10-year span, the researchers aimed to determine if resistance to these antibiotics increased over time.

Findings

  • Over the 10-year period, there was a significant increase in the MICs of Rhodococcus equi for both rifampin and erythromycin.
  • The MIC for rifampin markedly increased from 0.081 μg/ml in 1996 to 0.187 μg/ml in 2006.
  • Similarly, the MIC for erythromycin also saw an increase, moving from 0.258 μg/ml before 2000 to 0.583 μg/ml in 2006.

Implications

  • This upward trend in resistance suggests that in the future there might be challenges in treating infections caused by Rhodococcus equi, especially in foals, using the currently available antibiotics.
  • This issue is furthermore complicated by the limited number of drugs able to combat Rhodococcus equi infection due to the bacteria’s ability to exist intracellularly. To be effective, treatments not only have to penetrate the bacterium’s robust polysaccharide cell wall but also the alveolar macrophages where the bacterium can survive.

Cite This Article

APA
Buckley T, McManamon E, Stanbridge S. (2007). Resistance studies of erythromycin and rifampin for Rhodococcus equi over a 10-year period. Ir Vet J, 60(12), 728-731. https://doi.org/10.1186/2046-0481-60-12-728

Publication

ISSN: 0368-0762
NlmUniqueID: 0100762
Country: Ireland
Language: English
Volume: 60
Issue: 12
Pages: 728-731

Researcher Affiliations

Buckley, T
  • Irish Equine Centre, Johnstown, Naas, Co, Kildare, Ireland. tbuckley@equine-centre.ie.
McManamon, E
    Stanbridge, S

      References

      This article includes 19 references
      1. Ainsworth DM, Beck KA, Boatwright CE, Snedden KA, Rebhun WC. Lack of residual lung damage in horses in which Rhodococcus equi-induced pneumonia had been diagnosed.. Am J Vet Res 1993 Dec;54(12):2115-20.
        pubmed: 8116948
      2. Ainsworth DM, Eicker SW, Yeagar AE, Sweeney CR, Viel L, Tesarowski D, Lavoie JP, Hoffman A, Paradis MR, Reed SM, Erb HN, Davidow E, Nalevanko M. Associations between physical examination, laboratory, and radiographic findings and outcome and subsequent racing performance of foals with Rhodococcus equi infection: 115 cases (1984-1992).. J Am Vet Med Assoc 1998 Aug 15;213(4):510-5.
        pubmed: 9713534
      3. Asoh N, Watanabe H, Fines-Guyon M, Watanabe K, Oishi K, Kositsakulchai W, Sanchai T, Kunsuikmengrai K, Kahintapong S, Khantawa B, Tharavichitkul P, Sirisanthana T, Nagatake T. Emergence of rifampin-resistant Rhodococcus equi with several types of mutations in the rpoB gene among AIDS patients in northern Thailand.. J Clin Microbiol 2003 Jun;41(6):2337-40.
      4. Bertone JJ, Reed SM, Bayly WM. Pneumonia and otherdisorders associated with Rhodococcus equi. Equine Internal Medicine 1998; pp. 970–979.
      5. Fines M, Pronost S, Maillard K, Taouji S, Leclercq R. Characterization of mutations in the rpoB gene associated with rifampin resistance in Rhodococcus equi isolated from foals.. J Clin Microbiol 2001 Aug;39(8):2784-7.
      6. Giguère S, Hondalus MK, Yager JA, Darrah P, Mosser DM, Prescott JF. Role of the 85-kilobase plasmid and plasmid-encoded virulence-associated protein A in intracellular survival and virulence of Rhodococcus equi.. Infect Immun 1999 Jul;67(7):3548-57.
      7. Hillidge CJ. Use of erythromycin-rifampin combination in treatment of Rhodococcus equi pneumonia.. Vet Microbiol 1987 Aug;14(3):337-42.
        doi: 10.1016/0378-1135(87)90121-0pubmed: 3314109google scholar: lookup
      8. Jacks S, Giguère S, Gronwall PR, Brown MP, Merritt KA. Pharmacokinetics of azithromycin and concentration in body fluids and bronchoalveolar cells in foals.. Am J Vet Res 2001 Dec;62(12):1870-5.
        doi: 10.2460/ajvr.2001.62.1870pubmed: 11763173google scholar: lookup
      9. Jacks SS, Giguère S, Nguyen A. In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials.. Antimicrob Agents Chemother 2003 May;47(5):1742-5.
      10. Kedlaya I, Ing M. Rhodococcus equi. 2007.
      11. Kenney DG, Robbins SC, Prescott JF, Kaushik A, Baird JD. Development of reactive arthritis and resistance to erythromycin and rifampin in a foal during treatment for Rhodococcus equi pneumonia.. Equine Vet J 1994 May;26(3):246-8.
      12. Mousel MR, Harrison L, Donahue JM, Bailey E. Rhodococcus equi and genetic susceptibility: assessing transferrin genotypes from paraffin-embedded tissues.. J Vet Diagn Invest 2003 Sep;15(5):470-2.
        pubmed: 14535549doi: 10.1177/104063870301500512google scholar: lookup
      13. Nordmann P, Ronco E. In-vitro antimicrobial susceptibility of Rhodococcus equi.. J Antimicrob Chemother 1992 Apr;29(4):383-93.
        doi: 10.1093/jac/29.4.383pubmed: 1607327google scholar: lookup
      14. Prescott JF. Epidemiology of Rhodococcus equi infection in horses.. Vet Microbiol 1987 Aug;14(3):211-4.
        doi: 10.1016/0378-1135(87)90107-6pubmed: 3314106google scholar: lookup
      15. Prescott JF. Rhodococcus equi: an animal and human pathogen.. Clin Microbiol Rev 1991 Jan;4(1):20-34.
        pmc: PMC358176pubmed: 2004346doi: 10.1128/cmr.4.1.20google scholar: lookup
      16. Prescott JF. Immunodeficiency and serious pneumonia in foals: the plot thickens.. Equine Vet J 1993 Mar;25(2):88-9.
      17. Prescott JF, Baggot JD. Antimicrobial Therapy in Veterinary Medicine. 2. Iowa State University Press, Iowa; 1993.
      18. Takai S, Takeda K, Nakano Y, Karasawa T, Furugoori J, Sasaki Y, Tsubaki S, Higuchi T, Anzai T, Wada R, Kamada M. Emergence of rifampin-resistant Rhodococcus equi in an infected foal.. J Clin Microbiol 1997 Jul;35(7):1904-8.
      19. Todar K. Antimicrobial agents used in treatment of infectious disease. 2002.

      Citations

      This article has been cited 11 times.
      1. Lord J, Carter C, Smith J, Locke S, Phillips E, Odoi A. Antimicrobial resistance among Streptococcus equi subspecies zooepidemicus and Rhodococcus equi isolated from equine specimens submitted to a diagnostic laboratory in Kentucky, USA. PeerJ 2022;10:e13682.
        doi: 10.7717/peerj.13682pubmed: 36164606google scholar: lookup
      2. Nielsen SS, Bicout DJ, Calistri P, Canali E, Drewe JA, Garin-Bastuji B, Gonzales Rojas JL, Gortázar C, Herskin M, Michel V, Miranda Chueca MÁ, Padalino B, Pasquali P, Roberts HC, Spoolder H, Ståhl K, Velarde A, Viltrop A, Winckler C, Baldinelli F, Broglia A, Kohnle L, Alvarez J. Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): antimicrobial-resistant Rhodococcus equi in horses. EFSA J 2022 Feb;20(2):e07081.
        doi: 10.2903/j.efsa.2022.7081pubmed: 35136423google scholar: lookup
      3. Álvarez-Narváez S, Huber L, Giguère S, Hart KA, Berghaus RD, Sanchez S, Cohen ND. Epidemiology and Molecular Basis of Multidrug Resistance in Rhodococcus equi. Microbiol Mol Biol Rev 2021 May 19;85(2).
        doi: 10.1128/MMBR.00011-21pubmed: 33853933google scholar: lookup
      4. Awosile BB, Heider LC, Saab ME, McClure JT. Antimicrobial resistance in bacteria isolated from horses from the Atlantic Provinces, Canada (1994 to 2013). Can Vet J 2018 Sep;59(9):951-957.
        pubmed: 30197437
      5. Fenton CS, Buckley TC. Minimum inhibitory concentrations of erythromycin and rifampin for Rhodococcus equi during the years 2007-2014. Ir Vet J 2015;68:23.
        doi: 10.1186/s13620-015-0051-4pubmed: 26445669google scholar: lookup
      6. Gressler LT, de Vargas AC, da Costa MM, Pötter L, da Silveira BP, Sangioni LA, de Avila Botton S. Genotypic and phenotypic detection of efflux pump in Rhodococcus equi. Braz J Microbiol 2014;45(2):661-5.
      7. Schlusselhuber M, Torelli R, Martini C, Leippe M, Cattoir V, Leclercq R, Laugier C, Grötzinger J, Sanguinetti M, Cauchard J. The equine antimicrobial peptide eCATH1 is effective against the facultative intracellular pathogen Rhodococcus equi in mice. Antimicrob Agents Chemother 2013 Oct;57(10):4615-21.
        doi: 10.1128/AAC.02044-12pubmed: 23817377google scholar: lookup
      8. Schlusselhuber M, Jung S, Bruhn O, Goux D, Leippe M, Leclercq R, Laugier C, Grötzinger J, Cauchard J. In vitro potential of equine DEFA1 and eCATH1 as alternative antimicrobial drugs in rhodococcosis treatment. Antimicrob Agents Chemother 2012 Apr;56(4):1749-55.
        doi: 10.1128/AAC.05797-11pubmed: 22232283google scholar: lookup
      9. Guerrero R, Bhargava A, Nahleh Z. Rhodococcus equi venous catheter infection: a case report and review of the literature. J Med Case Rep 2011 Aug 9;5:358.
        doi: 10.1186/1752-1947-5-358pubmed: 21827681google scholar: lookup
      10. Baptiste KE, Kyvsgaard NC, Ahmed MO, Damborg P, Dowling PM. Is Rifampin (Rifampicin) Essential for the Treatment of Rhodococcus equi Infections in Foals? A Critical Review of the Role of Rifampin. J Vet Pharmacol Ther 2025 Sep;48(5):345-358.
        doi: 10.1111/jvp.70007pubmed: 40552784google scholar: lookup
      11. Alvarez Narvaez S, Sanchez S. Exploring the Accessory Genome of Multidrug-Resistant Rhodococcus equi Clone 2287. Antibiotics (Basel) 2023 Nov 17;12(11).
        doi: 10.3390/antibiotics12111631pubmed: 37998833google scholar: lookup